Immunomodulation of periodontitis with SPMs

Inflammation is a critical component in the pathophysiology of numerous disease processes, with most therapeutic modalities focusing on its inhibition in order to achieve treatment outcomes. The resolution of inflammation is a separate, distinct pathway that entails the reversal of the inflammatory process to a state of homoeostasis rather than selective inhibition of specific components of the inflammatory cascade. The discovery of specialized pro-resolving mediators (SPMs) resulted in a paradigm shift in our understanding of disease etiopathology. Periodontal disease, traditionally considered as one of microbial etiology, is now understood to be an inflammation-driven process associated with dysbiosis of the oral microbiome that may be modulated with SPMs to achieve therapeutic benefit.

Automated summary

Inflammation is a crucial part of many disease processes, and most treatments aim to inhibit inflammation for therapeutic outcomes. The resolution of inflammation involves reversing the inflammatory process to a state of homeostasis instead of selectively inhibiting specific components of the inflammatory cascade. The discovery of specialized pro-resolving mediators (SPMs) has revolutionized our understanding of the pathophysiology of diseases. Periodontal disease, previously thought to be caused by microbes, is now recognized as an inflammation-driven process associated with dysbiosis of the oral microbiome, which can be modulated with SPMs for therapeutic benefits.